Technical Analysis for MLLCF - Molecular Partners Ag

Grade Last Price % Change Price Change
D 25.25 1.00% 0.2500
MLLCF closed up 1.0 percent on Tuesday, April 13, 2021, on 22 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Up
Historical MLLCF trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Gapped Up Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.00%
Narrow Range Bar Range Contraction 1.00%
NR7 Range Contraction 1.00%
Inside Day Range Contraction 1.00%
Fell Below 20 DMA Bearish 2.23%
Fell Below 50 DMA Bearish 2.23%
180 Bearish Setup Bearish Swing Setup 2.23%
Older End-of-Day Signals for MLLCF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Molecular Partners Ag Description

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Partnership Drugs Biopharmaceutical Solid Tumors Stage Biopharmaceutical Pharmaceutical Companies Restore Cancer Immunotherapy Tumor Macular Degeneration Multiple Myeloma Amgen Macular Edema Mge Diabetic Macular Edema Wet Age Related Macular Degeneration Allergan Vascular Endothelial Growth Factor Vascular Endothelial Growth Factor A

Is MLLCF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 33.0
52 Week Low 16.0
Average Volume 5,367
200-Day Moving Average 0.0000
50-Day Moving Average 25.9931
20-Day Moving Average 25.1059
10-Day Moving Average 24.9575
Average True Range 1.0440
ADX 11.51
+DI 28.7118
-DI 20.2492
Chandelier Exit (Long, 3 ATRs ) 23.9180
Chandelier Exit (Short, 3 ATRs ) 25.9020
Upper Bollinger Band 26.4815
Lower Bollinger Band 23.7303
Percent B (%b) 0.55
BandWidth 10.9584
MACD Line -0.0213
MACD Signal Line -0.1191
MACD Histogram 0.0978
Fundamentals Value
Market Cap 550.69 Million
Num Shares 21.8 Million
EPS
Price-to-Sales 32.91
Price-to-Book 15.37
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.0600
Resistance 3 (R3) 26.1500 25.9700 25.9250
Resistance 2 (R2) 25.9700 25.7637 25.9250 25.8800
Resistance 1 (R1) 25.6100 25.6363 25.5200 25.5200 25.8350
Pivot Point 25.4300 25.4300 25.3850 25.3850 25.4300
Support 1 (S1) 25.0700 25.2237 24.9800 24.9800 24.6650
Support 2 (S2) 24.8900 25.0963 24.8450 24.6200
Support 3 (S3) 24.5300 24.8900 24.5750
Support 4 (S4) 24.4400